Borealis appoints IMCD as Bormed™ healthcare portfolio distributor

Borealis appoints IMCD as Bormed™ healthcare portfolio distributor
Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European distributor of its dedicated grade range of Bormed™ polyolefins for healthcare. The distribution agreement covers most of Europe (with the exception of Switzerland and the South-Eastern countries1) and takes effect as of 1 October 2021.

It applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices.

As a distributor with strong presence in medical and healthcare applications, IMCD is the ideal partner for Borealis customers in Europe thanks to its broad technical expertise and dedicated medical application team. The extensive IMCD polymers range complements the Borealis Bormed portfolio, opening a range of new possibilities. IMCD was selected from a broad field of potential distributors following a rigorous screening process.

“We are pleased to have found in IMCD a partner sharing the core Bormed values of service, commitment and conformance,” said John Webster, Borealis Head of Sales Advanced Products. “What also unites us is our dedication to providing best-in-class service to all of our healthcare customers, both direct and indirect, by way of more intensive and efficient value chain collaboration. We are confident that this new agreement will significantly boost our presence in this increasingly important sector.”

IMCD Czech republic s.r.o. - cooperation with BOREALIS  
   

In line with its commitment to service as the foundation of successful industry co-operation, Borealis and IMCD will together ensure a seamless distribution transition for their customers, who can continue to count on security of supply as well as the ready assistance of experienced technical and sales teams.

Olivier Champault, Director of IMCD Business Group Advanced Materials: “We are delighted to be selected as the new partner for Borealis in their healthcare business. This partnership is completely aligned with our strategy to further expand and strengthen our presence in the medical and healthcare segment in Europe. With our dedicated experts in medical and healthcare applications, our well-establish distribution network, and our board product offering, we are fully committed to accelerate growth and to support our customers in their developments and innovations.”

Author: IMCD Czech republic s.r.o.

You Might Also Be Interested In

Record 330 million euros. Slovnaft's investments were also directed to the modification of technologies for the processing of various types of crude oil

24.2.2025 Skupina SLOVNAFT investovala v roku 2024 do údržby, úprav a modernizácie svojich výrobných zariadení najväčší objem peňazí vo svojej histórii 
– 330 miliónov eur. Išlo najmä o úpravu technológií z dôvodu diverzifikácie...